Orbis Allan Gray Ltd lowered its position in shares of Allergan PLC. (NYSE:AGN) by 0.0% during the third quarter, according to its most recent filing with the SEC. The fund owned 1,007,578 shares of the company’s stock after selling 144 shares during the period. Allergan PLC. comprises approximately 1.6% of Orbis Allan Gray Ltd’s investment portfolio, making the stock its 20th largest position. Orbis Allan Gray Ltd’s holdings in Allergan PLC. were worth $232,055,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Atlas Brown Inc. boosted its stake in Allergan PLC. by 56.0% in the second quarter. Atlas Brown Inc. now owns 3,209 shares of the company’s stock worth $742,000 after buying an additional 1,152 shares in the last quarter. Essex Financial Services Inc. boosted its stake in Allergan PLC. by 25.8% in the second quarter. Essex Financial Services Inc. now owns 1,580 shares of the company’s stock worth $365,000 after buying an additional 324 shares in the last quarter. Tealwood Asset Management Inc. boosted its stake in Allergan PLC. by 5.3% in the second quarter. Tealwood Asset Management Inc. now owns 7,048 shares of the company’s stock worth $1,629,000 after buying an additional 355 shares in the last quarter. Roberts Glore & Co. Inc. IL purchased a new stake in Allergan PLC. during the second quarter worth about $1,186,000. Finally, Retirement Design & Management Inc. ADV boosted its stake in Allergan PLC. by 15.7% in the second quarter. Retirement Design & Management Inc. ADV now owns 1,977 shares of the company’s stock worth $457,000 after buying an additional 269 shares in the last quarter. Institutional investors and hedge funds own 86.40% of the company’s stock.
Allergan PLC. (NYSE:AGN) opened at 246.76 on Tuesday. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $301.32. The company has a market capitalization of $92.55 billion, a P/E ratio of 6.46 and a beta of 1.07. The company’s 50 day moving average price is $220.50 and its 200-day moving average price is $222.70.
Allergan PLC. (NYSE:AGN) last released its earnings results on Wednesday, February 8th. The company reported $3.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.76 by $0.14. The company earned $3.86 billion during the quarter, compared to analyst estimates of $3.77 billion. Allergan PLC. had a return on equity of 7.21% and a net margin of 100.04%. Allergan PLC.’s quarterly revenue was up 7.1% on a year-over-year basis. During the same period in the prior year, the company posted $3.41 earnings per share. Equities analysts forecast that Allergan PLC. will post $16.03 earnings per share for the current fiscal year.
This report was first posted by sleekmoney and is owned by of sleekmoney. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright laws. The legal version of this report can be read at http://sleekmoney.com/orbis-allan-gray-ltd-reduces-position-in-allergan-plc-agn/1659968.html.
A number of analysts have recently issued reports on AGN shares. Barclays PLC restated an “equal weight” rating and set a $250.00 price objective on shares of Allergan PLC. in a research report on Monday, October 31st. Mizuho lowered their price target on Allergan PLC. from $299.00 to $293.00 and set a “buy” rating on the stock in a research report on Tuesday, November 1st. Credit Suisse Group reiterated an “outperform” rating and issued a $329.00 price target on shares of Allergan PLC. in a research report on Thursday, November 3rd. Royal Bank Of Canada lowered their price target on Allergan PLC. from $300.00 to $279.00 and set an “outperform” rating on the stock in a research report on Thursday, November 3rd. Finally, Morgan Stanley lowered their price target on Allergan PLC. from $300.00 to $274.00 and set an “overweight” rating on the stock in a research report on Thursday, November 3rd. Eight analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $272.01.
In other news, Director Nesli Basgoz sold 500 shares of the company’s stock in a transaction that occurred on Thursday, December 8th. The stock was sold at an average price of $188.72, for a total value of $94,360.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Brent L. Saunders bought 5,250 shares of Allergan PLC. stock in a transaction dated Monday, November 21st. The stock was acquired at an average cost of $189.13 per share, with a total value of $992,932.50. The disclosure for this purchase can be found here. Corporate insiders own 0.27% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/orbis-allan-gray-ltd-reduces-position-in-allergan-plc-agn/1659968.html
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.